Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Myelodysplastic Syndromes
Interventions: Lenalidomide, Luspatercept; Drug
Lead sponsor: Mikkael Sekeres, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Conditions: Myelodysplastic Syndrome
Interventions: Birinapant, 5-Azacitidine; Drug
Lead sponsor: TetraLogic Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Glendale, Arizona • Scottsdale, Arizona • Fresno, California + 4 more

Conditions: Advanced Solid Tumours
Interventions: EBC-129, Pembrolizumab; Drug
Lead sponsor: EDDC (Experimental Drug Development Centre), A*STAR Research Entities; Government
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Houston, Texas

Conditions: Hepatitis C, Depression
Interventions: Depression collaborative care model; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Little Rock, Arkansas • West Los Angeles, California • St Louis, Missouri + 1 more

Conditions: Acute Coronary Syndrome, STEMI, STEMI - ST Elevation Myocardial Infarction, Acute Coronary Artery Thrombosis (Diagnosis), NSTEMI - Non-ST Segment Elevation MI, Non-ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction, Non ST Segment Elevation Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction (nSTEMI), Non STEMI
Interventions: No intervention; Other
Lead sponsor: Stony Brook University; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Stony Brook, New York

Conditions: Breast Cancer, Lung Cancer, GI Cancer
Interventions: Pharmacy Intervention, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more

Conditions: Dentin Sensitivity, Oral Hygiene
Interventions: Test Dentifrice, Reference Dentifrice (Aquafresh Cavity Protection); Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Advanced Solid Tumors
Interventions: Avelumab, M9241, Avelumab (Once weekly), M9241 (MTD), Avelumab (Expansion cohort); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: San Diego, California • Santa Rosa, California • New Haven, Connecticut + 13 more

Conditions: Dermatitis Atopic
Interventions: PF-07038124 and Vehicle, PF-07038124 or vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity, Insulin Resistance
Interventions: Metabolically abnormal obese - Mediterranean diet, Metabolically abnormal obese - Low carbohydrate ketogenic diet, Metabolically abnormal obese - Plant-based, very-low-fat diet, Annual Follow-up Visits; Other · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Smoking Cessation
Interventions: Nicotine Film, Placebo Nicotine Film; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more

Conditions: Healthy Subjects
Interventions: E2609, itraconazole, rifampin, digoxin, donepezil; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cardiovascular Disease
Interventions: AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Metastatic Melanoma
Interventions: IN10018, Cobimetinib, Atezolizumab; Drug · Biological
Lead sponsor: InxMed (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: Coronavirus, Covid19
Interventions: Soterix taVNS model 0125-LTE Stimulator - Active-Active Group, Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 2 more

Conditions: Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
Interventions: Tazemetostat; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Cancer of the Breast, Anomaly of Breast
Interventions: Autologous Fat Grafting of the Breast, Control Arm; Procedure · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Clackamas, Oregon

Conditions: Stuttering, Developmental, Dyslexia, Healthy Participants
Interventions: Unpredictable auditory feedback perturbation: 2 behavioral sessions, Unpredictable auditory feedback perturbation during tCS: 3 behavioral sessions, Sustained F1 auditory feedback perturbation, Sustained F0 auditory feedback perturbation, Reflexive somatosensory perturbation, Anodal tCS targeting pSTG and vSSC, Anodal tCS targeting left or right vPMC, Sham tCS targeting pSTG or vSSC, Sham tCS targeting left vPMC or right vPMC; Behavioral · Other
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions: BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Long Beach, California • San Diego, California • Milford, Connecticut + 10 more

Search by objective public record fields.

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

A Study of EBC-129 in Advanced Solid Tumours

Hepatitis C Translating Initiatives for Depression Into Effective Solutions

EKG Criteria and Identification of Acute Coronary Occlusion

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health

Pharmacokinetics of Nicotine Film in Smokers

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis

Lurbinectedin + Doxorubicin In Leiomyosarcoma

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

A Study of TAK-951 in Healthy Adults

Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects

Investigating Individual Differences in Speech Motor Skills in Neurotypical Speakers and Persons With Disordered Speech

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants